LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer. - Langley, R.E.; Nankivell, M.; Gilbert, D.; Bourmpaki, E.; Mangar, S.; Rush, H.L.; Rosen, S.D.; Alhasso, A.; Kockelbergh, R.; Marshall, J.; Griffiths, A.; Chan, K.H.Y.; et al. (Annals of Oncology, 2024)